Oragenics, Inc. — FY 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 1, 2021. The filing also presents unaudited quarterly results. Oragenics is a clinical-stage biotechnology company with no product revenue, focused on the Terra CoV-2 vaccine candidate and lantibiotic antibiotic development.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $22.11 million | $12.12 million |
| General and administrative expense | $4.53 million | $3.76 million |
| Total operating expenses | $26.64 million | $15.88 million |
| Net loss | $26.43 million | $15.57 million |
| Basic and diluted loss per share | $0.47 | $0.37 |
| Cash used in operating activities | $16.95 million | $13.01 million |
- Fourth-quarter 2020 revenue was $0; operating expenses were $4.55 million and net loss was $4.41 million, versus $3.66 million and $3.60 million, respectively, in fourth-quarter 2019. Quarterly figures are unaudited.
- At year-end, cash and cash equivalents were $17.64 million, working capital was $16.64 million, total assets were $18.68 million, and shareholders’ equity was $16.84 million. No gross margin is reported because the company had no revenue.
- Year-end liabilities included $228,000 of short-term notes and $670,700 of operating lease liabilities. Cash flow was funded principally by equity offerings and warrant exercises; the company reported no material long-term borrowings.
- Management estimated that year-end cash, subsequent ATM proceeds and warrant-exercise proceeds, less the planned Series C redemption, would fund operations as presently structured through the second quarter of 2022. The company nevertheless expects continued losses and says further financing will be required.
Material changes and significant items
- Net loss rose 69.8% year over year, with R&D expense up 82.4%. The increase primarily reflected the Noachis Terra acquisition and Terra CoV-2 development; the acquisition was accounted for as an asset purchase, with $9.96 million of consideration for in-process R&D expensed in 2020.
- G&A expense increased 20.7%. The company also recorded $132,753 of income from forgiveness of its Paycheck Protection Program loan and accrued interest.
- Cash declined by $628,000 during 2020 despite $16.32 million of financing cash inflows. Common shares outstanding increased from 46.12 million at year-end 2019 to 91.77 million at year-end 2020.
- After year-end, the company raised approximately $19.3 million net through an at-the-market offering through February 12, 2021, received $2.26 million gross from warrant exercises through February 25, and gave notice to redeem all Series C preferred stock for approximately $5.6 million on March 13, 2021. Shares outstanding were 109.65 million as of February 25, 2021.
Outlook, programs and key risks
- Terra CoV-2: The vaccine remained preclinical. Management anticipated filing an IND in fourth-quarter 2021 and beginning Phase 1 after FDA clearance; further development depends on additional funding, grants, partnerships or licensing. FDA feedback broadly supported the planned preclinical approach, but is not an approval. The company described potential refrigerated distribution and one- or two-dose use as expected product attributes, not established clinical results.
- OG716: The oral lantibiotic candidate for C. difficile also remained preclinical. IND timing depends on funding and completion of required studies, including manufacturing and preclinical work. Promising efficacy described in the filing is from animal studies; no human clinical trials had begun.
- Funding and execution: Oragenics has never generated product revenue and expects substantial ongoing losses. BARDA funding was denied; other government funding is uncertain. Limited internal vaccine-development and manufacturing capabilities, reliance on contract manufacturers and collaborators, and potential delays or cost increases are material risks.
- Competition and market uncertainty: COVID-19 vaccines were already authorized and being distributed by competitors, while many other candidates were in development. Pandemic evolution, variants, competing products, or reduced demand could impair Terra CoV-2’s commercial opportunity. Antibiotic development also faces clinical, regulatory and commercial uncertainty.
- Licenses and obligations: The NIH vaccine license is nonexclusive, and its covered patent applications had not yet issued. The Lantibiotic ECC provides for 10% of net sales and 25% of sublicense revenue to EGI, plus cash milestones of $25 million for regulatory approval and $5 million each for a new indication and a new product; none had been achieved as of December 31, 2020.
- Dilution and contingencies: The filing reported 20.51 million warrants outstanding at year-end, in addition to convertible preferred stock and options. The Noachis Terra acquisition also includes contingent payments tied to certain warrant exercises; an additional $542,263 was paid after year-end following exercises. The company disclosed no material legal proceedings.
- The independent auditor issued an unqualified opinion on the financial statements and identified the accounting classification of Noachis Terra acquisition warrants as a critical audit matter. Management reported effective controls; the auditor did not attest to their effectiveness.
Important facts for investors to verify
- Whether the planned Terra CoV-2 IND and Phase 1 timetable was achieved, and whether the candidate’s safety, efficacy, manufacturability and differentiation are supported by subsequent data.
- Cash burn, current liquidity and actual runway after the ATM financing, warrant proceeds, Series C redemption and continued R&D spending; confirm whether additional capital or a partner is needed.
- The scale and terms of potential dilution from outstanding warrants, options and convertible preferred stock, including the post-period share-count increase.
- Progress and financing for OG716’s remaining preclinical and manufacturing studies, and the status of the NIH and EGI licenses, milestones and royalty obligations.
- Whether reported animal-study findings and management’s market, storage and dosing expectations translate into reproducible clinical outcomes and a viable commercial opportunity.